Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jun 1;99(11):2672–2681. doi: 10.1172/JCI119456

Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

T Ebara 1, R Ramakrishnan 1, G Steiner 1, N S Shachter 1
PMCID: PMC508113  PMID: 9169497

Abstract

The mechanism of apolipoprotein (apo) CIII-induced hypertriglyceridemia remains uncertain. We crossed apoCIII transgenic and apoE gene knockout (apoE0) mice, and observed severe hypertriglyceridemia with plasma triglyceride levels of 4,521+/-6, 394 mg/dl vs. 423+/-106 mg/dl in apoE0 mice, P < 0.00001 for log(triglycerides [TG]). Cholesterols were 1,181+/-487 mg/dl vs. 658+/-151 mg/dl, P < 0.0001. Lipoprotein fractionation showed a marked increase in triglyceride-enriched chylomicrons+VLDL. This increase was limited to the lowest density (chylomicrons and Sf 100-400) subfractions. Intermediate density lipoproteins (IDL)+LDL increased moderately, and HDL decreased. There was no significant increase in triglyceride production in apoCIII transgenic/apoE0 mice. The clearance of VLDL triglycerides, however, was significantly decreased. Lipoprotein lipase in postheparin plasma was elevated, but activation studies suggested LPL inhibition by both apoCIII transgenic and apoCIII transgenic/apoE0 plasma. ApoCIII overexpression also produced a marked decrease in VLDL glycosaminoglycan binding which was independent of apoE. The predominant mechanism of apoCIII-induced hypertriglyceridemia appears to be decreased lipolysis at the cell surface. The altered lipoprotein profile that was produced also allowed us to address the question of the direct atherogenicity of chylomicrons and large VLDL. Quantitative arteriosclerosis studies showed identical results in both apoCIII transgenic/apoE0 and apoE0 mice, supporting the view that very large triglyceride-enriched particles are not directly atherogenic.

Full Text

The Full Text of this article is available as a PDF (260.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aalto-Setälä K., Fisher E. A., Chen X., Chajek-Shaul T., Hayek T., Zechner R., Walsh A., Ramakrishnan R., Ginsberg H. N., Breslow J. L. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992 Nov;90(5):1889–1900. doi: 10.1172/JCI116066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Austin M. A., Hokanson J. E. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am. 1994 Jan;78(1):99–115. doi: 10.1016/s0025-7125(16)30178-x. [DOI] [PubMed] [Google Scholar]
  3. Baginsky M. L., Brown W. V. Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma. J Lipid Res. 1977 Jul;18(4):423–437. [PubMed] [Google Scholar]
  4. Benlian P., De Gennes J. L., Foubert L., Zhang H., Gagné S. E., Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med. 1996 Sep 19;335(12):848–854. doi: 10.1056/NEJM199609193351203. [DOI] [PubMed] [Google Scholar]
  5. Brown W. V., Baginsky M. L. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972 Jan 31;46(2):375–382. doi: 10.1016/s0006-291x(72)80149-9. [DOI] [PubMed] [Google Scholar]
  6. Brown W. V., Levy R. I., Fredrickson D. S. Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J Biol Chem. 1970 Dec 25;245(24):6588–6594. [PubMed] [Google Scholar]
  7. Brown W. V., Levy R. I., Fredrickson D. S. Studies of the proteins in human plasma very low density lipoproteins. J Biol Chem. 1969 Oct 25;244(20):5687–5694. [PubMed] [Google Scholar]
  8. Carlson L. A., Ballantyne D. Changing relative proportions of apolipoproteins CII and CIII of very low density lipoproteins in hypertriglyceridaemia. Atherosclerosis. 1976 May-Jun;23(3):563–568. doi: 10.1016/0021-9150(76)90016-2. [DOI] [PubMed] [Google Scholar]
  9. Clark A. B., Quarfordt S. H. Apolipoprotein effects on the lipolysis of perfused triglyceride by heparin-immobilized milk lipase. J Biol Chem. 1985 Apr 25;260(8):4778–4783. [PubMed] [Google Scholar]
  10. Clavey V., Lestavel-Delattre S., Copin C., Bard J. M., Fruchart J. C. Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol. 1995 Jul;15(7):963–971. doi: 10.1161/01.atv.15.7.963. [DOI] [PubMed] [Google Scholar]
  11. Dammerman M., Sandkuijl L. A., Halaas J. L., Chung W., Breslow J. L. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4562–4566. doi: 10.1073/pnas.90.10.4562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. FOLCH J., LEES M., SLOANE STANLEY G. H. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957 May;226(1):497–509. [PubMed] [Google Scholar]
  13. Forte T. M., Nichols A. V., Krauss R. M., Norum R. A. Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. J Clin Invest. 1984 Nov;74(5):1601–1613. doi: 10.1172/JCI111576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Garbers D. L. Guanylyl cyclase receptors and their endocrine, paracrine, and autocrine ligands. Cell. 1992 Oct 2;71(1):1–4. doi: 10.1016/0092-8674(92)90258-e. [DOI] [PubMed] [Google Scholar]
  15. Ginsberg H. N., Jones J., Blaner W. S., Thomas A., Karmally W., Fields L., Blood D., Begg M. D. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1829–1838. doi: 10.1161/01.atv.15.11.1829. [DOI] [PubMed] [Google Scholar]
  16. Ginsberg H. N., Le N. A., Goldberg I. J., Gibson J. C., Rubinstein A., Wang-Iverson P., Norum R., Brown W. V. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986 Nov;78(5):1287–1295. doi: 10.1172/JCI112713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Groot P. H., van Stiphout W. A., Krauss X. H., Jansen H., van Tol A., van Ramshorst E., Chin-On S., Hofman A., Cresswell S. R., Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb. 1991 May-Jun;11(3):653–662. doi: 10.1161/01.atv.11.3.653. [DOI] [PubMed] [Google Scholar]
  18. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hamilton R. L., Moorehouse A., Havel R. J. Isolation and properties of nascent lipoproteins from highly purified rat hepatocytic Golgi fractions. J Lipid Res. 1991 Mar;32(3):529–543. [PubMed] [Google Scholar]
  20. Havel R. J., Fielding C. J., Olivecrona T., Shore V. G., Fielding P. E., Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry. 1973 Apr 24;12(9):1828–1833. doi: 10.1021/bi00733a026. [DOI] [PubMed] [Google Scholar]
  21. Hayek T., Masucci-Magoulas L., Jiang X., Walsh A., Rubin E., Breslow J. L., Tall A. R. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995 Oct;96(4):2071–2074. doi: 10.1172/JCI118255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ito Y., Azrolan N., O'Connell A., Walsh A., Breslow J. L. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 1990 Aug 17;249(4970):790–793. doi: 10.1126/science.2167514. [DOI] [PubMed] [Google Scholar]
  23. Karpe F., Steiner G., Uffelman K., Olivecrona T., Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994 Mar;106(1):83–97. doi: 10.1016/0021-9150(94)90085-x. [DOI] [PubMed] [Google Scholar]
  24. Kowal R. C., Herz J., Weisgraber K. H., Mahley R. W., Brown M. S., Goldstein J. L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 1990 Jun 25;265(18):10771–10779. [PubMed] [Google Scholar]
  25. Landis B. A., Rotolo F. S., Meyers W. C., Clark A. B., Quarfordt S. H. Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase. Am J Physiol. 1987 Jun;252(6 Pt 1):G805–G810. doi: 10.1152/ajpgi.1987.252.6.G805. [DOI] [PubMed] [Google Scholar]
  26. Le N. A., Gibson J. C., Ginsberg H. N. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins. J Lipid Res. 1988 May;29(5):669–677. [PubMed] [Google Scholar]
  27. Li W. W., Dammerman M. M., Smith J. D., Metzger S., Breslow J. L., Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995 Dec;96(6):2601–2605. doi: 10.1172/JCI118324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Maeda N., Li H., Lee D., Oliver P., Quarfordt S. H., Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994 Sep 23;269(38):23610–23616. [PubMed] [Google Scholar]
  29. Nordestgaard B. G., Zilversmit D. B. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res. 1988 Nov;29(11):1491–1500. [PubMed] [Google Scholar]
  30. Pagnan A., Havel R. J., Kane J. P., Kotite L. Characterization of human very low density lipoproteins containing two electrophoretic populations: double pre-beta lipoproteinemia and primary dysbetalipoproteinemia. J Lipid Res. 1977 Sep;18(5):613–622. [PubMed] [Google Scholar]
  31. Patsch J. R., Miesenböck G., Hopferwieser T., Mühlberger V., Knapp E., Dunn J. K., Gotto A. M., Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb. 1992 Nov;12(11):1336–1345. doi: 10.1161/01.atv.12.11.1336. [DOI] [PubMed] [Google Scholar]
  32. Plump A. S., Scott C. J., Breslow J. L. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9607–9611. doi: 10.1073/pnas.91.20.9607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Purcell-Huynh D. A., Farese R. V., Jr, Johnson D. F., Flynn L. M., Pierotti V., Newland D. L., Linton M. F., Sanan D. A., Young S. G. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995 May;95(5):2246–2257. doi: 10.1172/JCI117915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Quarfordt S. H., Michalopoulos G., Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem. 1982 Dec 25;257(24):14642–14647. [PubMed] [Google Scholar]
  35. Ramakrishnan R., Arad Y., Wong S., Ginsberg H. N. Nonuniform radiolabeling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B. J Lipid Res. 1990 Jun;31(6):1031–1042. [PMC free article] [PubMed] [Google Scholar]
  36. Rapp J. H., Harris H. W., Hamilton R. L., Krupski W. C., Reilly L. M., Ehrenfeld W. K., Stoney R. J., Goldstone J., Kane J. P. Particle size distribution of lipoproteins from human atherosclerotic plaque: a preliminary report. J Vasc Surg. 1989 Jan;9(1):81–88. [PubMed] [Google Scholar]
  37. Rees A., Stocks J., Sharpe C. R., Vella M. A., Shoulders C. C., Katz J., Jowett N. I., Baralle F. E., Galton D. J. Deoxyribonucleic acid polymorphism in the apolipoprotein A-1-C-III gene cluster. Association with hypertriglyceridemia. J Clin Invest. 1985 Sep;76(3):1090–1095. doi: 10.1172/JCI112062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Rensen P. C., van Berkel T. J. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem. 1996 Jun 21;271(25):14791–14799. doi: 10.1074/jbc.271.25.14791. [DOI] [PubMed] [Google Scholar]
  39. Sane T., Nikkilä E. A. Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal. Arteriosclerosis. 1988 May-Jun;8(3):217–226. doi: 10.1161/01.atv.8.3.217. [DOI] [PubMed] [Google Scholar]
  40. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991 Sep 25;266(27):18259–18267. [PubMed] [Google Scholar]
  41. Shachter N. S., Ebara T., Ramakrishnan R., Steiner G., Breslow J. L., Ginsberg H. N., Smith J. D. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J Clin Invest. 1996 Aug 1;98(3):846–855. doi: 10.1172/JCI118857. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Shachter N. S., Hayek T., Leff T., Smith J. D., Rosenberg D. W., Walsh A., Ramakrishnan R., Goldberg I. J., Ginsberg H. N., Breslow J. L. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994 Apr;93(4):1683–1690. doi: 10.1172/JCI117151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sharrett A. R., Chambless L. E., Heiss G., Paton C. C., Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 1995 Dec;15(12):2122–2129. doi: 10.1161/01.atv.15.12.2122. [DOI] [PubMed] [Google Scholar]
  44. Simpson H. S., Williamson C. M., Olivecrona T., Pringle S., Maclean J., Lorimer A. R., Bonnefous F., Bogaievsky Y., Packard C. J., Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 1990 Dec;85(2-3):193–202. doi: 10.1016/0021-9150(90)90111-u. [DOI] [PubMed] [Google Scholar]
  45. Wang C. S., McConathy W. J., Kloer H. U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 1985 Feb;75(2):384–390. doi: 10.1172/JCI111711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Weinstock P. H., Bisgaier C. L., Aalto-Setälä K., Radner H., Ramakrishnan R., Levak-Frank S., Essenburg A. D., Zechner R., Breslow J. L. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest. 1995 Dec;96(6):2555–2568. doi: 10.1172/JCI118319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Weisgraber K. H., Mahley R. W., Kowal R. C., Herz J., Goldstein J. L., Brown M. S. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990 Dec 25;265(36):22453–22459. [PubMed] [Google Scholar]
  48. Windler E. E., Kovanen P. T., Chao Y. S., Brown M. S., Havel R. J., Goldstein J. L. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J Biol Chem. 1980 Nov 10;255(21):10464–10471. [PubMed] [Google Scholar]
  49. Windler E., Chao Y., Havel R. J. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins. J Biol Chem. 1980 Sep 10;255(17):8303–8307. [PubMed] [Google Scholar]
  50. Zhang S. H., Reddick R. L., Piedrahita J. A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992 Oct 16;258(5081):468–471. doi: 10.1126/science.1411543. [DOI] [PubMed] [Google Scholar]
  51. de Silva H. V., Lauer S. J., Wang J., Simonet W. S., Weisgraber K. H., Mahley R. W., Taylor J. M. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 1994 Jan 21;269(3):2324–2335. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES